Q-omics provides the consensus-scored ECHDC2 profile across patient tissues and cancer cell-line models. ECHDC2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, ECHDC2 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, ECHDC2 protein abundance shows 22,413 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, and LSCC as cancer lineages where ECHDC2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ECHDC2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ECHDC2 survival associations across molecular data types. ECHDC2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ECHDC2 RNA expression–survival associations across cancer types. High ECHDC2 expression shows unfavorable associations in LGG and PRAD, but favorable associations in HNSC, BLCA, MESO and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for ECHDC2 RNA expression.
This table summarizes ECHDC2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ECHDC2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ECHDC2 shows lower tumor expression in HNSC, KICH, KIRP, THCA, BRCA and UCEC. The HNSC box plot shows higher ECHDC2 RNA expression in normal versus tumor tissue (log2 FC = −1.453, t-test p < 0.001).
This table shows molecular features associated with ECHDC2 in patient tissues and cancer cell lines. In patient samples, ECHDC2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ECHDC2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in OVARY and UPPER_AERODIGESTIVE_TRACT.
